People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Pharmaceuticals, Biotechnology, Other Health Care, Medical Devices, Biotech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $352.5M | $2.8B | 2021 |
| Avenzo Therapeutics, Inc. | — | Biotechnology | Series D+ | $270.6M | $355.7M | 2022 |
| Genocea Biosciences, Inc. | — | Biotechnology | Series C | $153.6M | $3.0B | 2010 |
| Principia Biopharma Inc. | — | Biotechnology | Series C | $77.4M | $2.0B | 2015 |
| Auxogyn Inc | — | Other Health Care | Series B | $73.1M | $327.3M | 2012 |
| Htg Molecular Diagnostics, Inc | — | Medical Devices | Series B | $65.3M | $110.4M | 2014 |
| Rezo Therapeutics, Inc. | — | Biotechnology | Series C | $46.3M | $868.3M | 2022 |
| CRISPR Therapeutics AG | — | Biotech | Series B | $36.0M | $39.7M | 2020 |
Simeon George at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Simeon George on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 2 | 24 |
| Ali Behbahani | 2 | 17 |
| Judith Li | 2 | 8 |
| Asish Xavier | 1 | 18 |
| Peter Thompson | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| Kevin Bitterman | 1 | 15 |
| LEON CHEN | 1 | 15 |
| William Clark | 1 | 12 |
| Fred Cohen | 1 | 12 |
| Srinivas Akkaraju | 1 | 10 |
| BRADLEY BOLZON | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Peter Bisgaard | 1 | 9 |
| Michael Higgins | 1 | 9 |
| Greg Garfield | 1 | 8 |
| Vineeta Agarwala | 1 | 8 |
| Chen Yu | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| Stephen Hoffman | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.